Nicox S.A. (ALCOX.PA)

EUR 0.22

(-4.48%)

Revenue Summary of Nicox S.A.

Nicox S.A.'s latest annual revenue in 2023 was 257 Thousand EUR , up 21.23% from previous year.
Nicox S.A.'s latest quarterly revenue in 2023 FY was 257 Thousand EUR , up 21.23% from previous quarter.
Nicox S.A. reported a annual revenue of 212 Thousand EUR in annual revenue 2022, down -97.53% from previous year.
Nicox S.A. reported a annual revenue of 8.58 Million EUR in annual revenue 2021, down -40.49% from previous year.
Nicox S.A. reported a quarterly revenue of 257 Thousand EUR for 2023 FY, up 21.23% from previous quarter.
Nicox S.A. reported a quarterly revenue of 866.50 EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Nicox S.A. (2023 - 2019)

Historical Annual Revenue of Nicox S.A. (2023 - 2019)

Year	Revenue	Revenue Growth
2023	257 Thousand EUR	21.23%
2022	212 Thousand EUR	-97.53%
2021	8.58 Million EUR	-40.49%
2020	14.42 Million EUR	0.0%
2019	- EUR	0.0%

Year	Revenue	Revenue Growth
2023 Q1	866.50 EUR	-5.87%
2023 FY	257 Thousand EUR	21.23%
2023 Q2	866.50 EUR	0.0%
2022 FY	212 Thousand EUR	-97.53%
2022 Q4	920.50 EUR	0.0%
2021 FY	8.58 Million EUR	-40.49%
2020 FY	14.42 Million EUR	0.0%
2019 FY	- EUR	0.0%

Peer Revenue Comparison of Nicox S.A.

Name	Revenue	Revenue Difference
European Medical Solutions	40.56 Million EUR	99.366%
FERMENTALG	4.05 Million EUR	93.665%
argenx SE	1.13 Billion EUR	99.977%
BioSenic S.A.	543 Thousand EUR	52.67%
Celyad Oncology SA	102 Thousand EUR	-151.961%
Hyloris Pharmaceuticals SA	2.08 Million EUR	87.686%
Onward Medical N.V.	532 Thousand EUR	51.692%
Oxurion NV	263 Thousand EUR	2.281%
PHAXIAM Therapeutics S.A.	1.32 Million EUR	80.618%
Financière de Tubize SA	- EUR	-Infinity%
UCB SA	5.25 Billion EUR	99.995%